Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Labor calls on Tasmanian government to release winter plan, as influenza cases increase on April 17, 2019 at 8:00 pm
Labor is calling on the state government to reveal details of how it plans to deal with increased demand on hospitals during flu season. So far this year there have been 448 of reported cases of ... […]
- Influenza Medication Market Analysis & Forecast 2019| Daiichi Sankyo Company, GlaxoSmithKline, Natco Pharma, F. Hoffmann-La Roche on April 17, 2019 at 4:05 pm
The report on the global Influenza Medication market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers ... […]
- Five more people die from influenza in San Diego this season on April 17, 2019 at 3:42 pm
SAN DIEGO (KGTV) — Five more people died from the flu in San Diego last week. The new deaths, ranging in people aged from 47- to 77-years-old, all had underlying health conditions, according to the ... […]
- Swine Influenza Vaccines 2019 Global Trends, Market Size, Share, Status, SWOT Analysis and Forecast to 2025 on April 17, 2019 at 12:42 am
The global Swine Influenza Vaccines market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to ... […]
- Global Swine Influenza Vaccines Market Prospective Growth, Opportunities, Top Key Players and Forecast to 2025 on April 17, 2019 at 12:35 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- WiseGuyRerports.com Presents "Global Swine Influenza Vaccines Market Insights, Forecast to 2025" New Document to its Studies Database The global Swine ... […]
- The role of platelets in mediating a response to human influenza infection on April 16, 2019 at 2:12 am
Influenza infection increases the incidence of myocardial infarction but the reason is unknown. Platelets mediate vascular occlusion through thrombotic functions but are also recognized to have ... […]
- Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology on April 15, 2019 at 5:30 am
SUMMIT, N.J., April 15, 2019 /PRNewswire/ -- Seqirus, a leading innovator in influenza protection, today announced it will file an Annual Strain Update with the U.S. Food and Drug Administration (FDA) ... […]
- Mechanism to form influenza A virus discovered on April 9, 2019 at 5:59 am
The influenza A virus is known to form new strains every year. These strains are the result of small variations occurring at the level of the genome, which cause the virus to change and become ... […]
- Influenza A virus ribonucleoproteins form liquid organelles at endoplasmic reticulum exit sites on April 9, 2019 at 2:17 am
Influenza A virus has an eight-partite RNA genome that during viral assembly forms a complex containing one copy of each RNA. Genome assembly is a selective process driven by RNA-RNA interactions and ... […]
via Bing News